(CIX: WRAL30)  1,016.48  down arrow-1.26  (-0.12 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: Apple)  93.70  down arrow-0.57  (-0.6 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: QUINTILES)  59.00  up arrow+0.65  (1.11 %)  Updated: 06:40 PM EST, Feb 11 2016
(OP: BASF SE)  64.80  up arrow+0.15  (0.24 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: BioCryst)  1.66  down arrow-0.14  (-7.78 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: BioDelivery)  3.53  up arrow+0.04  (1.15 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: CEMP)  16.53  down arrow-0.07  (-0.42 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: Cisco)  24.68  up arrow+2.17  (9.64 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: Cree)  28.44  down arrow-0.86  (-2.94 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: DARA)  0.88    (0 %)  Updated: 08:10 PM EST, Dec 04 2015
(NY: EMC)  24.16  down arrow-0.39  (-1.59 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: Extreme Networks)  2.35  down arrow-0.13  (-5.24 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: Facebook)  101.91  up arrow+0.91  (0.9 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: GLAXOSMITHKLINE)  39.15  up arrow+0.02  (0.05 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: Alphabet)  683.11  down arrow-1.01  (-0.15 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: IBM)  117.85  down arrow-2.34  (-1.95 %)  Updated: 06:40 PM EST, Feb 11 2016
(NY: LH)  101.40  down arrow-3.19  (-3.05 %)  Updated: 06:40 PM EST, Feb 11 2016
(OP: Lenovo Group)  15.91  down arrow-0.73  (-4.39 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: MRK)  48.85  down arrow-0.68  (-1.37 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: Microsoft)  49.69  down arrow-0.02  (-0.04 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: NetApp)  21.73  down arrow-0.65  (-2.9 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: NOVARTIS AG)  72.20  down arrow-0.79  (-1.08 %)  Updated: 06:40 PM EST, Feb 11 2016
(OP: Novozymes A/S)  41.16  down arrow-0.16  (-0.38 %)  Updated: 05:20 PM EST, Feb 11 2016
(NY: Pfizer)  29.13  down arrow-0.36  (-1.22 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: POZN)  5.94    (0 %)  Updated: 08:10 PM EST, Feb 05 2016
(NY: Red Hat)  61.97  down arrow-1.57  (-2.47 %)  Updated: 06:40 PM EST, Feb 11 2016
(NQ: BBRY)  6.62  down arrow-0.03  (-0.38 %)  Updated: 05:20 PM EST, Feb 11 2016
(NQ: Salix)  172.81    (0 %)  Updated: 08:10 PM EDT, Apr 01 2015
(NQ: SQI)  11.85  down arrow-0.18  (-1.5 %)  Updated: 05:20 PM EST, Feb 11 2016

Posts tagged “Local Firms”

Updated 2:59 p.m. today

RTP virtual reality group, American Underground team up for demos

RTPVR A group of startups focusing on virtual reality known as RTP Virtual Reality is teaming up with the American Underground for a series of demos to demonstrate what has been touted as the next wave in interactive entertainment. Several Triangle firms already are making plays in the VR space.

Updated 10:54 a.m. today

Premium Lock Want a job in the 'Next Evolution'? Try analytics

Help wanted sign        With robots, more automation and the rise of cognitive computing being predicted to erase hundreds of thousands of jobs in North Carolina over the next generation, a new report predicts growing job demand in one area: Analytics. Companies need hundreds of thousands of data scientists and data managers as they broaden use of analytics across the enterprise. At Cisco, the search is on for internal talent.

Updated 7:47 a.m. today

Quintiles earnings beat Street forecasts; CEO upbeat

Quintiles            Quintiles reports quarterly earnings that top Wall Street expectations, and the business pipeline has CEO Tom Pike upbeat. "We believe we are well-positioned for the long-term with our $12.04 billion of backlog," he says.

6:20 a.m. yesterday

Report: SEC investigating former Salix executives

Salix        The former CEO and CFO of Salix Pharmaceuticals, which was sold to Valeant Pharmaceuticals for more than $11 billion a year ago, are being investigated by the SEC, according to the Reuters news service.

1:11 p.m. Tuesday

Premium Lock Novozymes reorganizes; changes may create some new jobs

Novozymes Novozymes, a global company focusing on enzyme development and production, is reorganizing. Its North America leader explains what's happening and says there will be some new jobs as a result.

12:07 p.m. Tuesday

Premium Lock Durham-based Chimerix reports progress in smallpox vaccine

Bioterror     Chimerix, which has a contract potentially worth more than $400 million in the development of a first vaccine targeting smallpox, reports progress in development of an antiviral. In recent tests, its brincidofovir successfully treated 100 percent of animals infected with rabbitpox.

Updated 6:25 a.m. Tuesday

Pozen name disappears after merger is closed

Pozen The name Pozen has disappeared following the closing of the merger between the Chapel Hill-based pharmaceutical firm and Canada-based Tribute.

2:35 p.m. Monday

Premium Lock Inside Lenovo: Finding ways to overcome PC market woes is a priority

Lenovo's gaming-geared laptop  Analysis: Lenovo's latest earnings report highlights the challenges the world's No. 1 PC maker faces as inorganic growth disappears. So says Technology Business Research analyst Jack Narcotta.

2:16 p.m. Monday

WTW news in review: Week of Feb. 1, part two

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for the week of Feb. 1, part two of two:

2:10 p.m. Monday

WTW news in review: Week of Feb. 1, part one

Week in review Here's a look back at technology, life science and other related news as reported in WRAL TechWire for the week of Feb. 1, part one of two.

Updated February 6

At Super Bowl, Lenovo will power NFL's tech lineup

Lenovo won't be running a multi-million-dollar ad Sunday night, but the world's No. 1 PC manufacturer is the NFL's "official computer provider" and thus will be a major technology player in Super Bowl 50's delivery. For example, if a player is injured a Lenovo Workstation will be used to help analyze what happened. And there's much more as the NFL notes in a case study.

February 5

Premium Lock CEO: ChannelAdvisor's remix is paying off - 'I feel pretty good'

ChannelAdvisor Ecommerce services provider ChannelAdvisor's CEO David Spitz delivers a spirited pep talk to Wall Street analysts after the Triangle born-and-grown to IPO company grew revenues 21 percent in 2015. After a shift in focus to larger companies, a retooling of the firm's sales force and with an acquisition paying off, Spitz is very bullish entering 2016.

February 4

Quintiles exec on immunotherapy: 'It's working'

Cancer research  In observance of Feb. 4 as "World Cancer Day," Terry Murdock, the head of the Oncology Center of Excellence at Quintiles, writes in a blog that "there is much to celebrate" this year in the fight against cancer.

Updated February 4

SAS drives revenue to 40th straight record: $3.16B

Driven by increased sales globally, a surge in new customers and a near 10 percent increase in R&D spending to develop new products, Cary-based SAS set a record for revenue in 2015 at $3.16 billion. Revenues grew 2.3 percent despite a strong U.S. dollar as the privately held firm also stretched its streak of never losing money. The good news means SAS is adding jobs.

Tracking SAS financials Tracking SAS financials

Updated February 3

Big drop in revenue triggers 11% plunge in Lenovo shares

Lenovo is doing well in India Lenovo, which is fighting a global downward trend in PC sales and has seen its smartphone sales fall sharply, is taking a beating in the stock market today after reporting an 8 percent drop in revenues for 2015's year-ending quarter. Layoffs and cost-cutting helped improve profits, however, the company notes.

February 3

Premium Lock Inside Lenovo: Enterprise Group, cost discipline keys to weathering challenges

Earnings    Analysis: Lenovo disclosed revenues today that fell below analysts' expectations, triggering an 11 percent drop in its stock. But the company did report a bigger-than-expected profit, something the world's No. 1 PC seller attributed largely to cost cuts. So what's happening to Lenovo? Our Insiders get an in-depth analysis.

Updated February 3

GSK posts $616M loss for 4th quarter; CEO sees 'substantial progress'

GSK in Zebulon  British-based drugmaker GlaxoSmithKline (NYSE: GSK) posted a loss of $616 million for the fourth quarter of 2015 - compared with a profit of over $1 for the same period a year earlier- as the company moved to integrate new businesses. Its top exec says GSK is making progress.

February 2

Premium Lock GSK expands cancer drug development deal with Adaptimmune

Cancer research  GlaxoSmithKline, which sold its oncology portfolio to Novartis in 2014, is expanding a development deal with Adaptimmune to explore possible cancer treatments. GSK announces earnings on Wednesday.

February 2

Premium Lock GSK invests in another startup fund along with J&J

GSK's HQ in London             GlaxoSmithKline, which is under growing investor pressure to improve its financials, is investing alongside Johnson & Johnson in another startup fund. For the second time in a week, GSK moves to back new and emerging ventures in hopes of driving future growth.

February 1

Premium Lock Report: Tablet sales plunge but 'detachables' offer hope

Tablet sales plunged more than 10 percent in 2015, including a 14 percent drop in the fourth quarter. But sales of "detachables" - on which Lenovo is betting heavily - are a bright spot, according to research firm IDC.

The latest Yoga from Lenovo The latest Yoga from Lenovo

Techwire Inside Partners
The Skinny: A Blog by Rick Smith